​

Phathom Pharmaceuticals Ownership | Who Owns Phathom Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Phathom Pharmaceuticals Ownership Summary


Phathom Pharmaceuticals is owned by 79.70% institutional investors, 4.61% insiders, and 15.70% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 15.19% of PHAT shares. Invesco OFI Global Equity is the top mutual fund, with 2.94% of its assets in Phathom Pharmaceuticals shares.

PHAT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockPhathom Pharmaceuticals79.70%4.61%15.70%
SectorHealthcare Stocks 129.40%12.08%-41.48%
IndustryBiotech Stocks 181.71%11.69%-93.40%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Frazier life sciences management12.47M15.19%$135.26M
Medicxi ventures management (jersey)7.46M8.91%$54.49M
Blackrock funding, inc. /de5.25M6.26%$38.30M
Blackrock2.93M5.01%$30.14M
Vanguard group3.18M4.33%$52.71M
Carlyle group3.50M4.18%$25.53M
Millennium management3.38M4.11%$36.63M
Vanguard capital management2.74M3.27%$19.97M
Franklin resources2.41M2.87%$13.67M
Gw&k investment management2.13M2.54%$15.54M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Medicxi ventures management (jersey)7.46M43.02%$54.49M
Catalys pacific1.88M6.55%$13.74M
Propel bio management1.11M4.28%$8.07M
Penn mutual asset management62.80K3.50%$681.40K
Frazier life sciences management12.47M2.95%$135.26M
Ghost tree capital600.00K1.94%$6.18M
Nea management company1.96M1.34%$21.27M
683 capital management1.85M0.99%$20.07M
Avidity partners management lp200.00K0.35%$2.17M
Jones hill capital lp276.83K0.34%$2.02M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group1.78M0.00%1.15M
Point72 asset management1.02M0.01%1.02M
Blackrock funding, inc. /de5.25M0.00%721.13K
Hsbc709.70K0.00%709.70K
Franklin resources2.41M0.00%435.56K

Top Sellers

HolderShares% AssetsChange
Jennison associates---7.04M
Invesco30.56K--4.00M
Checkpoint capital---2.27M
Portolan capital management---1.70M
Orbimed advisors---1.45M

New Positions

HolderShares% AssetsChangeValue
Point72 asset management1.02M0.01%1.02M$11.09M
Hsbc709.70K0.00%709.70K$7.70M
Opaleye management185.59K0.18%185.59K$2.01M
Schroder investment management group101.75K0.00%101.75K$1.11M
Entropy technologies, lp73.53K0.02%73.53K$536.78K

Sold Out

HolderChange
Ifp advisors-1.00
Hughes financial services-1.00
Clearstead advisors-5.00
Nelson, van denburg & campbell wealth management group-7.00
Stone house investment management-8.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2026153-11.56%66,742,824-7.93%791.06%883.53%36-28.00%
Jun 30, 2026171-4.47%72,438,0915.15%880.99%82-28.07%5130.77%
Mar 31, 2026174-1.69%68,392,19810.38%931.32%11214.29%38-25.49%
Dec 31, 2025101-26.28%40,864,285-34.45%550.75%56-22.22%307.14%
Sep 30, 202574-37.82%29,531,937-48.16%400.66%37-40.32%18-45.45%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Invesco OFI Global Equity2.34M2.94%-
Invesco Global A2.34M2.90%-
Jennison Health Sciences Equity1.78M2.56%-
Vanguard Total Stock Mkt Idx Inv2.01M2.52%-
Vanguard Morn Total Stk Mkt Idx Investor2.01M2.48%-
Vanguard MStar Total Stk Mkt Idx Invest2.01M2.48%-
Vanguard US Total Market Shares ETF1.65M2.36%280.90K
Jennison SMid Cap Core Equity1.58M2.27%-
Strategic Advisers U.S. Total Stock{mg}1.48M2.16%-273.72K
Strategic Advisers Small-Mid Cap1.24M1.82%278.88K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 03, 2025Breedlove Robert Charles Principal Accounting OfficerSell$7.08K
Sep 05, 2025Breedlove Robert Charles Principal Accounting OfficerSell$5.57K
Jul 16, 2025Breedlove Robert Charles Principal Accounting OfficerSell$14.15K
May 21, 2025Topper James N-Buy$14.61K
May 14, 2025Topper James N-Buy$20.92K

Insider Transactions Trends


DateBuySell
2026 Q4--
2026 Q3--
2026 Q2--
2026 Q1--
2025 Q4-1

PHAT Ownership FAQ


Who Owns Phathom Pharmaceuticals?

Phathom Pharmaceuticals shareholders are primarily institutional investors at 79.70%, followed by 4.61% insiders and 15.69% retail investors. The average institutional ownership in Phathom Pharmaceuticals's industry, Biotech Stocks , is 181.71%, which Phathom Pharmaceuticals falls below.

Who owns the most shares of Phathom Pharmaceuticals?

Phathom Pharmaceuticals’s largest shareholders are Frazier life sciences management (12.47M shares, 15.19%), Medicxi ventures management (jersey) (7.46M shares, 8.91%), and Blackrock funding, inc. /de (5.25M shares, 6.26%). Together, they hold 30.37% of Phathom Pharmaceuticals’s total shares outstanding.

Does Blackrock own Phathom Pharmaceuticals?

Yes, BlackRock owns 5.01% of Phathom Pharmaceuticals, totaling 2.93M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 30.14M$. In the last quarter, BlackRock increased its holdings by 180.99K shares, a 6.59% change.

Who is Phathom Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Medicxi ventures management (jersey) is Phathom Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 43.02% of its assets in 7.46M Phathom Pharmaceuticals shares, valued at 54.49M$.

Who is the top mutual fund holder of Phathom Pharmaceuticals shares?

Invesco OFI Global Equity is the top mutual fund holder of Phathom Pharmaceuticals shares, with 2.94% of its total shares outstanding invested in 2.34M Phathom Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools